Drug Profile

Vopimetostat - Tango Therapeutics

Alternative Names: TNG-462

Latest Information Update: 14 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tango Therapeutics
Class Alkanes; Amides; Aminopyridines; Antineoplastics; Benzothiazoles; Ketones; Piperidines; Small molecules
Mechanism of Action PRMT5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer; Soft tissue sarcoma
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Adenocarcinoma; Non-small cell lung cancer; Solid tumours
Preclinical Cancer

Most Recent Events

05 Nov 2025 Chemical structure information added.
24 Oct 2025 Tango Therapeutics announces intention discuss trial with US FDA for Pancreatic cancer
24 Oct 2025 Updated efficacy data from a phase I/II trial in Solid tumours released by Tango Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com